Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

Kazuto Ashizawa



Author of

  • +

    P1.03 - Chemotherapy/Targeted Therapy (ID 689)

    • Event: WCLC 2017
    • Type: Poster Session with Presenters Present
    • Track: Chemotherapy/Targeted Therapy
    • Presentations: 1
    • +

      P1.03-015 - The Relationship between the UGT1A1*27 and UGT1A1*7 Genetic Polymorphisms and Irinotecan-Related Toxicities in Patients with Lung Cancer (ID 7500)

      09:30 - 16:00  |  Author(s): Kazuto Ashizawa

      • Abstract

      Background:
      Genetic polymorphisms in the UDP-glucuronosyltransferase 1A1 (UGT1A1), UGT1A7, and UGT1A9 genes are associated with interindividual differences in irinotecan toxicities. Purpose: To evaluate the effects of gene polymorphisms, including UGT1A1*7, *27, and *29, on the safety of irinotecan therapy.

      Method:
      The eligibility criteria were as follows: lung cancer patients who were scheduled to undergo irinotecan therapy, aged ≥20 years, and had a performance status of 0-2. After informed consent had been obtained, patients were enrolled, and their blood was collected and used to examine the frequency of the UGT1A1*6, *7, *27, *28, and *29 polymorphisms and the drug concentrations of irinotecan, SN-38, and SN-38G after irinotecan therapy.

      Result:
      Thirty-one patients were enrolled. The patients’ characteristics were as follows: male/female = 25/6, median age (range) = 71 (55-84), stage IIB/IIIA/IIIB/IV = 2/6/11/12, and Ad/Sq/Sm/Oth = 14/10/3/4. The -/-, *6/-, *7/-, *27/-, *28/-, and *29/- UGT1A1 gene polymorphisms were observed in 10 (32%), 10 (32%), 2 (6%), 2 (6%), 7 (23%), and 0 (0%) cases, respectively. There were no homozygous or complex heterozygous polymorphisms. The UGT1A1*27 polymorphism occurred separately from the UGT1A1*28 polymorphism. The lowest leukocyte counts of the patients with the UGT1A1*27 and UGT1A1*6 gene polymorphisms were lower than those seen in the wild-type patients. SN-38 tended to remain in the blood for a prolonged period after the infusion of irinotecan in patients with the UGT1A1*27 or UGT1A1*28 polymorphism. No severe myelotoxicity was seen in the patients with UGT1A1*7.

      Conclusion:
      UGT1A1*27 and UGT1A1*7 are both rare gene polymorphisms. UGT1A1*27 can occur separately from UGT1A1*28 in some circumstances and is related to leukopenia during irinotecan treatment. UGT1A1*7 is less relevant to irinotecan-induced toxicities, and UGT1A1*29 seems to have little clinical impact.

  • +

    WS 01 - IASLC Supporting the Implementation of Quality Assured Global CT Screening Workshop (By Invitation Only) (ID 632)

    • Event: WCLC 2017
    • Type: Workshop
    • Track: Radiology/Staging/Screening
    • Presentations: 1
    • +

      WS 01.31 - Japan (ID 10676)

      08:30 - 21:00  |  Presenting Author(s): Kazuto Ashizawa

      • Abstract
      • Slides

      Abstract:
      Cancer has been the most common cause of death since 1981, accounting for 30% of all deaths recently in Japan. The mortality rate of lung, pancreas, and colon/rectum has been increased, and lung cancer is the leading cause of cancer-related death in Japan as well as western countries. Therefore, smoking cessation as primary prevention should continue to be a major focus of public health campaigns. Moreover, early detection and treatment for lung cancer is one of the important issues in cancer care. According to the current guidelines for lung caner screening in Japan from Ministry of Health, Labour and Welfare, chest radiography (chest radiography and sputum cytology for heavy smokers) is recommended to perform as opportunistic screening as well as population-based screening due to a significant evidence of reduction of lung caner mortality rate based on the results of 4 case-control studies in 1990s in Japan. While, low-dose CT is not recommended to perform as population-based screening because the evidence of reduction of lung caner mortality rate is insufficient, but low-dose CT is accepted to perform as opportunistic screening with informed consents of its potential benefits and harms. In Japan, CT screening for lung cancer was initiated first in the world, and several single-group cohort studies found a high frequency of early stage lung cancer. After initial results of low-dose CT screening for lung cancer were reported, low-dose CT screening for lung cancer has been implemented at community and workplace settings. An ecological/time series study was performed in Hitachi area, where the largest-scale chest CT screening program for lung cancer has been introduced in Japan. This study, where non-/light smokers account for approximately half of the CT screening examinees, showed that wide implementation of CT screening can decrease lung cancer mortality at community level (figure 1). Currently, a randomized controlled trial (JECS Study) is underway in Japan with non-/light smokers as the subjects, and this trial is very important in terms of cancer prevention (figure 2). The interpretation of CT findings and the follow-up of undiagnosed nodules are to be carried out according to the guidelines from The Committee for Management of CT-screening-detected Pulmonary Nodules, The Japanese Society of CT Screening. In this lecture, I will talk about the current status of low-dose CT screening for lung cancer in Japan briefly. Figure 1Figure 2





      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    WS 02 - IASLC Symposium on the Advances in Lung Cancer CT Screening (Ticketed Session SOLD OUT) (ID 631)

    • Event: WCLC 2017
    • Type: Symposium
    • Track: Radiology/Staging/Screening
    • Presentations: 1
    • +

      WS 02.17 - Session 4: Lung Cancer Screening’s Impact on COPD and Smoking Cessation (ID 10590)

      09:00 - 18:15  |  Presenting Author(s): Kazuto Ashizawa

      • Abstract

      Abstract not provided